.jpg?format=webp&quality=80&width=3840)
The study aimed to understand the long-term cardiovascular benefits of lowering postprandial hyperglycemia (PPG). It followed 243 patients with early-stage Type 2 Diabetes Mellitus (T2DM) for 10 years after a randomized controlled trial. The results showed that voglibose or nateglinide did not reduce major adverse cardiovascular events (MACE) during the observational period. However, the improvement of PPG significantly reduced the occurrence of MACE and unplanned coronary revascularization in subjects with impaired glucose tolerance (IGT). The study concludes that early improvement of PPG can reduce cardiovascular risk in patients with IGT during a long-term follow-up period.
Like
Save
Share